• DAS28 [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  

• radiographic disease progression, physical functioning, QOL, treatment satisfaction, productivity and safety [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  

Subjects with ACR diagnosis of RA on stable dose of methotrexate for at least 24 months ready to start etanercept per approved product monograph

Inclusion Criteria:

18 years of age or older at the baseline visit An ACR diagnosis of rheumatoid arthritis with onset of symptoms of at least 6 months.

Active disease of at least 3 swollen joints at the baseline visit. A DAS28 score of > 3.2 at the baseline visit Have not previously received etanercept therapy. Able to start etanercept therapy per the approved product monograph Able to continue methotrexate therapy per the approved product monograph and have received a dose of at least 15 mg/wk for at least 24 weeks and this dose has been stable at least 4 weeks before the baseline visit.

The subject or legally acceptable representative must provide written informed consent for participation in the study before any study specific procedure are performed.

Exclusion Criteria:

Patients who have a positive purified protein derivative (PPD) skin test and who do not have a documented completed course of anti-tuberculosis therapy.

Patients who have previously received infliximab or adalimumab. Active infections within 2 weeks of the baseline visit or during the study period.

Any history of human immunodeficiency (HIV) infection, untreated tuberculosis, multiple sclerosis, congestive heart failure, hepatitis B, hepatitis C, cytopenia, prior or current use of cyclophosphamide or malignancy (other than basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix) in the past 5 years.

Women who are pregnant or lactating or of childbearing potential who are not using adequate contraception Receipt of any investigational therapy within 4 weeks of the initiation of study medication or during the study period.

Presence of any significant and uncontrolled medical condition, which in the investigator's opinion precludes the use of etanercept, as outline in the product monograph.

Subjects not available for follow-up assessment or unable to comply with study procedures.